Given our previous report on the preclinical activity of the alpha-specific PI3K inhibitor, alpelisib (Alpelisib, BYL719, Novartis) in NPC12,13, we explored if there is any synergistic effect on tumor growth when combining ribociclib with alpelisib. Here, PIK3CA is linked to neoplasm.